Arcutis Biotherapeutics, Inc. (ARQT) Dividend History

Company News

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has granted 72,000 restricted stock units to nine newly hired employees as an inducement to join the company.

  GlobeNewswire Inc.
• Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

  Arcutis Biotherapeutics presented new long-term data on its investigational ZORYVE cream 0.05% and approved ZORYVE cream 0.15% for the treatment of atopic dermatitis, showing durable efficacy and safety in children and adults.

  GlobeNewswire Inc.
• Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

  Arcutis Biotherapeutics reported strong Q1 2025 financial results, driven by continued demand growth for its ZORYVE portfolio. The company also provided updates on its pipeline and upcoming regulatory milestones.

  GlobeNewswire Inc.
• Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market

  The atopic dermatitis drugs market is projected to reach $31 billion by 2034, driven by the rising prevalence of the condition, advancements in biologic therapies, and growing awareness. The biologics segment led the market in 2024, with new biologic injections targeting inflammatory pathways expanding treatment options.

  GlobeNewswire Inc.

  Featured Companies: ABBV INCY LLY PFE REGN VTRS
• Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

  Arcutis Biotherapeutics announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting. The data demonstrated favorable safety and local tolerability of ZORYVE (roflumilast) cream 0.15% in adults and children with atopic dermatitis, and positive efficacy, safety, and local tolerability data for investigational ZORYVE (roflumilast) foam 0.3% in scalp and body psoriasis.

  GlobeNewswire Inc.